Paul Greaves

Paul Greaves

Auto-generated profile, based on publicly available information

Paul Greaves

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Blood
Verified
Journal Article
Open access
PDF file
PGPaul Greaves
Paul Greaves
JGJohn G. Gribben
John G. Gribben
The B7 family consists of structurally related, cell-surface proteins that regulate immune responses by delivering costimulatory or coinhibitory signals through their ligands. Eight family members have been identified to date including CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand [PD-L1]), CD273 (programmed cell death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and B7-H6. B7 ligands are expressed on both lymphoid and nonlymphoid tissues. The importance of the B7 family in regulating immune responses is clear from their demonstrated role in the development of immunodeficiency and autoimmune diseases. Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation.

17 October 2013 in Blood
Verified
Journal Article
Open access
PDF file
PGPaul Greaves
Paul Greaves
ACAndrew Clear
Andrew Clear
AOAndrew Owen
Andrew Owen
SISameena Iqbal
Sameena Iqbal
ALAbigail Lee
Abigail Lee
JGJohn G. Gribben
John G. Gribben
Key Points: Hodgkin lymphoma microenvironment T-helper cells express TH1/activation markers and lack TH2/immunosuppression markers. These cells are functional, retaining the capacity for cytokine secretion and proliferation in vitro.

10 January 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PGPaul Greaves
Paul Greaves
ACAndrew Clear
Andrew Clear
RCRita Coutinho
Rita Coutinho
AWAndrew Wilson
Andrew Wilson
JMJanet Matthews
Janet Matthews
JGJohn G. Gribben
John G. Gribben
Purpose: The immune microenvironment is key to the pathophysiology of classical Hodgkin lymphoma (CHL). Twenty percent of patients experience failure of their initial treatment, and others receive excessively toxic treatment. Prognostic scores and biomarkers have yet to influence outcomes significantly. Previous biomarker studies have been limited by the extent of tissue analyzed, statistical inconsistencies, and failure to validate findings. We aimed to overcome these limitations by validating recently identified microenvironment biomarkers (CD68, FOXP3, and CD20) in a new patient cohort with a greater extent of tissue and by using rigorous statistical methodology. Patients and Methods: Diagnostic tissue from 122 patients with CHL was microarrayed and stained, and positive cells were counted across 10 to 20 high-powered fields per patient by using an automated system. Two statistical analyses were performed: a categorical analysis with test/validation set-defined cut points and Kaplan-Meier estimated outcome measures of 5-year overall survival (OS), disease-specific survival (DSS), and freedom from first-line treatment failure (FFTF) and an independent multivariate analysis of absolute uncategorized counts. Results: Increased CD20 expression confers superior OS. Increased FOXP3 expression confers superior OS, and increased CD68 confers inferior FFTF and OS. FOXP3 varies independently of CD68 expression and retains significance when analyzed as a continuous variable in multivariate analysis. A simple score combining FOXP3 and CD68 discriminates three groups: FFTF 93%, 62%, and 47% (P < .001), DSS 93%, 82%, and 63% (P = .03), and OS 93%, 82%, and 59% (P = .002). Conclusion: We have independently validated CD68, FOXP3, and CD20 as prognostic biomarkers in CHL, and we demonstrate, to the best of our knowledge for the first time, that combining FOXP3 and CD68 may further improve prognostic stratification.

1 January 2014 in Blood Reviews
Verified
Journal Article
Closed access
DTDimitris A. Tsitsikas
Dimitris A. Tsitsikas
GGGiorgio Gallinella
Giorgio Gallinella
SPSneha Patel
Sneha Patel
HSHenry Seligman
Henry Seligman
PGPaul Greaves
Paul Greaves
RARoger J. Amos
Roger J. Amos

15 November 2013 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PGPaul Greaves
Paul Greaves
SSShah‐Jalal Sarker
Shah‐Jalal Sarker
KCKashfia Chowdhury
Kashfia Chowdhury
RJRachel Johnson
Rachel Johnson
JMJanet Matthews
Janet Matthews
TLT. Andrew Lister
T. Andrew Lister

25 November 2014 in Haematologica
Verified
Journal Article
Open access
PDF file
RCR. Coutinho
R. Coutinho
ACA. J. Clear
A. J. Clear
EME. Mazzola
E. Mazzola
AOA. Owen
A. Owen
PGP. Greaves
P. Greaves
JGJ. G. Gribben
J. G. Gribben
Gene expression studies have identified the microenvironment as a prognostic player in diffuse large B-cell lymphoma. However, there is a lack of simple immune biomarkers that can be applied in the clinical setting and could be helpful in stratifying patients. Immunohistochemistry has been used for this purpose but the results are inconsistent. We decided to reinvestigate the immune microenvironment and its impact using immunohistochemistry, with two systems of image analysis, in a large set of patients with diffuse large B-cell lymphoma. Diagnostic tissue from 309 patients was arrayed onto tissue microarrays. Results from 161 chemoimmunotherapy-treated patients were used for outcome prediction. Positive cells, percentage stained area and numbers of pixels/area were quantified and results were compared with the purpose of inferring consistency between the two semi-automated systems. Measurement cutpoints were assessed using a recursive partitioning algorithm classifying results according to survival. Kaplan-Meier estimators and Fisher exact tests were evaluated to check for significant differences between measurement classes, and for dependence between pairs of measurements, respectively. Results were validated by multivariate analysis incorporating the International Prognostic Index. The concordance between the two systems of image analysis was surprisingly high, supporting their applicability for immunohistochemistry studies. Patients with a high density of CD3 and FoxP3 by both methods had a better outcome. Automated analysis should be the preferred method for immunohistochemistry studies. Following the use of two methods of semi-automated analysis we suggest that CD3 and FoxP3 play a role in predicting response to chemoimmunotherapy in diffuse large B-cell lymphoma.